Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 3/20 | 0.81 |
| ▸ | MEN1 | O00255 | 5/20 | 0.80 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.80 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.80 |
| ▸ | TP53 | P04637 | 1/20 | 0.80 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.80 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.80 |
| ▸ | HPGD | P15428 | 1/20 | 0.80 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.80 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.80 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.80 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.69 |
| ▸ | MAPT | P10636 | 2/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.64 |
| ▸ | MITF | O75030 | 1/20 | 0.64 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.64 |
| ▸ | NPC1 | O15118 | 2/20 | 0.64 |
| ▸ | RAB9A | P51151 | 2/20 | 0.64 |
| ▸ | MGAM | O43451 | 2/20 | 0.62 |
| ▸ | GAA | P10253 | 2/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1639424 | 1.00 | NTRK1 (0.81) | NTRK1MEN1KMT2AKDM4ETP53 | |
| SCHEMBL1639422 | 1.00 | NTRK1 (0.81) | NTRK1MEN1KMT2AKDM4ETP53 | |
| SCHEMBL29695425 | 1.00 | NTRK1 (0.81) | NTRK1MEN1KMT2AKDM4ETP53 | |
| SCHEMBL13952237 | 0.92 | NOX4 (0.71) | NTRK1MEN1KMT2AKDM4ETP53 | |
| SCHEMBL18196458 | 0.90 | MEN1 (0.74) | NTRK1MEN1KMT2AKDM4ETP53 | |
| SCHEMBL28895208 | 0.90 | NTRK1 (1.00) | NTRK1MEN1KMT2AKDM4ETP53 | |
| SCHEMBL414436 | 0.89 | MEN1 (1.00) | NTRK1MEN1KMT2AKDM4ETP53 | |
| SCHEMBL76811 | 0.89 | MEN1 (1.00) | NTRK1MEN1KMT2AKDM4ETP53 | |
| SCHEMBL29599618 | 0.89 | MEN1 (1.00) | NTRK1MEN1KMT2AKDM4ETP53 | |
| SCHEMBL29379900 | 0.89 | MEN1 (1.00) | NTRK1MEN1KMT2AKDM4ETP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9296716-B2 | Androgen receptor ligands | THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, & THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIV. TRINITY OF QUEEN ELIZABETH NEAR DUBLIN (IE) | 2016-03-29 | — | — | US | disclosed |
| US-9296716-B2 | Androgen receptor ligands | THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, & THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIV. TRINITY OF QUEEN ELIZABETH NEAR DUBLIN (IE) | 2016-03-29 | — | — | US | disclosed |
| US-20140357682-A1 | ANDROGEN RECEPTOR LIGANDS | The Provost, Fellows, Foundation Scholars, & the Other Members of Board, of The College of the Holy (IE) | 2014-12-04 | — | — | US | disclosed |
| US-20140357682-A1 | ANDROGEN RECEPTOR LIGANDS | The Provost, Fellows, Foundation Scholars, & the Other Members of Board, of The College of the Holy (IE) | 2014-12-04 | — | — | US | disclosed |
| WO-2013076275-A1 | ANDROGEN RECEPTOR LIGANDS | THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, & THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY & UNDIV.TRINITY OF QUEEN ELIZABETH NEAR DUBLIN (IE) | 2013-05-30 | — | — | WO | disclosed |
| WO-2012027548-A1 | COMPOUNDS AND METHODS FOR PREVENTION AND TREATMENT OF ALZHEIMER'S AND OTHER DISEASES | THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH (US) | 2012-03-01 | — | — | WO | disclosed |
| US-20110098309-A1 | METHODS OF INHIBITING THE FORMATION OF AMYLOID-BETA DIFFUSABLE LIGANDS USING ACYLHYDRAZIDE COMPOUNDS | ACUMEN PHARMACEUTICALS, INC. (US) | 2011-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098309-A1 | METHODS OF INHIBITING THE FORMATION OF AMYLOID-BETA DIFFUSABLE LIGANDS USING ACYLHYDRAZIDE COMPOUNDS | APP, APBA1, BACE1 | NTRK1 1503/4885MEN1 2974/4885KMT2A 3625/4885 |
| US-20140357682-A1 | ANDROGEN RECEPTOR LIGANDS | AR, NR5A1, SHBG | NTRK1 244/4885MEN1 4657/4885KMT2A 3958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.